GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Shiller PE Ratio

GSTC (GlobeStar Therapeutics) Shiller PE Ratio : (As of Dec. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlobeStar Therapeutics Shiller PE Ratio Historical Data

The historical data trend for GlobeStar Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Shiller PE Ratio Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, GlobeStar Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Shiller PE Ratio falls into.



GlobeStar Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GlobeStar Therapeutics's E10 for the quarter that ended in Jun. 2024 is calculated as:

For example, GlobeStar Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0/132.5538*132.5538
=0.000

Current CPI (Jun. 2024) = 132.5538.

GlobeStar Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -0.300 100.428 -0.396
201412 -0.840 99.070 -1.124
201503 -0.980 99.621 -1.304
201506 -0.760 100.684 -1.001
201509 -0.033 100.392 -0.044
201512 -0.020 99.792 -0.027
201603 -0.020 100.470 -0.026
201606 0.000 101.688 0.000
201609 -0.110 101.861 -0.143
201612 -0.010 101.863 -0.013
201703 -0.010 102.862 -0.013
201706 -0.004 103.349 -0.005
201709 -0.020 104.136 -0.025
201712 -0.010 104.011 -0.013
201803 -0.001 105.290 -0.001
201806 -0.002 106.317 -0.002
201809 0.000 106.507 0.000
201812 -0.004 105.998 -0.005
201903 -0.002 107.251 -0.002
201906 0.000 108.070 0.000
201909 -0.012 108.329 -0.015
201912 -0.001 108.420 -0.001
202003 -0.001 108.902 -0.001
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 -0.002 111.754 -0.002
202106 -0.010 114.631 -0.012
202109 -0.010 115.734 -0.011
202112 -0.001 117.630 -0.001
202203 -0.001 121.301 -0.001
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 -0.002 128.729 -0.002
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 0.000 132.554 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlobeStar Therapeutics  (OTCPK:GSTC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GlobeStar Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550

GlobeStar Therapeutics Headlines